Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Silles - if you haven't done so already it's worth putting some time into looking at the differences between antigen and antibody tests. In summary there's two things you need to know:
1. Anti-body tests can in pricinple pick up current infection. However, by this time the infectious/most infectious period has already passed. The infectious period is two days before symptoms show through to seven days after symptoms show at which point the viral load begins to fall.
2. The UK Gov appear to have little to no interest in antibody tests. You're not going to stop the spread with them because people have done their spreading already by the time an antibody tests shows positive! Any attempt to use antibody tests as a passport to increased freedoms/holidays would end in disaster. We would have people who didn't feel they were at risk actively setting out to catch Covid-19, like children with chicken pox. This would leads to massively increased spread accross all demographics of people and would be disastrous. They are a tool for statistics and not much more.
That's my understanding too Pigster. Aside from the Heathrow trials (which are IMO mainly a publicity stunt by an airport to force the Government to move towards airport testing as soon as possible), there appears to be no other information currently available.
It doesn't mean they're not ahead, they could be..... there's just nothing to suggest they are. An ODX/Avacta deal would lead me to believe that Avacta are indeed ahead. Of course, even if Mologic are infront of us - they still need to manufacture on scale in order to take any meaningful market share - which is the big obstacle which Avacta are currently working through.
We have the power of Affimers on our side - this means we have a reagent which is easier to manfacture and on scale whilst also being robust. Anybody wishing to compete with Avacta will either need to use Affimers or find an equally good reagent with adequete availability.
I would be delighted to see a manufacturing partnership with ODX.
The Korean LFA is not looking promising due to low sensitivity and others failing with saliva and moving towards nasal swabs as already posted on this board.
The LFA antigen test we don't know much about is Mologic. If successful, ODX are lined up to manfacture it. If ODX sign up with Avacta, it would be a negative indicator for the mysterious Mologic test and a positive one for us.
Mixed emotions on Avacta today. On the one hand I'm very satisfied that everything is fine. On the other hand, seeing the share price down isn't great.
Any indication of a delay and the traders and rainbow chasers move on so that's exactly what has happened today. On a positive note, anybody looking to take a position is now crystal clear on where we are and the revised timelines. I believe this should provide some stability to the share price and hopefully stop the very annoying drop which any non LFA RNS has been creating.
Any fears of bad news should now be gone. We know everything is fine and the clock is reset. Onwards and upwards from here!
Looking to make an application with the FDA. Need to work on manufacturing capacity before the opportunity can be exploited, though. It's a relatively straightforward pathway once already CE marked in Europe.
Avacta are legal manufacturer of the LFA and will hold the CE mark.
Cytiva are a materials company. They only supply the strip, similar to how Avacta supply the Affimers. They're not a manufacturer.
With BBI and Abbingdon, probably capacity of 5 to 10 millions per month as it stands today. But this can be increased to many tens of millions per month and other partners can be brought on board. Total capacity including oversees unknown, but Sir Al believes there's potential to meet the hundreds of millions per month - however a lot of due dilligence must be done with these oversees companies first.
Very interesting idea about the LFA tests being used at testing stations as triage to reduce the number of tests which need to be conducted by PCR...
I don't believe any of us had even considered that a possibility. Brilliant idea, though!
Merchantwnker, go back to the ODX board.
7th Sep RNS:
"Avacta remains focused on the much larger opportunity of the saliva-based coronavirus antigen rapid test that we are developing with Cytiva and which is now in the process of technology transfer to our manufacturing partners. "
Today's RNS simply re-confirms everything which we already knew. Nothing has changed and nothing bad has happened - infact, everything is great - especially with the updated broker target. Clearly massive upside here within a matter of weeks.
Not nailed on, but as close to nailed on as one could reasonably expect.
Sir Al gives a good presentation. I'm really looking forward to it even though I don't think we'll learn anything new. We might however have some 'read between the lines' teasers or some excitement/body language indications.
I'm very interested to see what questions are chosen for the Q&A. We know the market is totally focussed on the LFA. They'll have to play this carefully for obvious reasons.